Michael Kelly
CIK: 0001952533
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)2 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
SPRY
ARS Pharmaceuticals, Inc.
Director
Discretionary Trading P&L
Holdings
About Kelly Michael
Kelly Michael (SEC CIK 0001952533) files insider reports with the SEC as Director of ARS Pharmaceuticals, Inc. (SPRY).
Signal8 holds 2 ownership filings by Kelly Michael, all Form 4s, filed between Jun 27, 2025 and Jun 26, 2026. Those filings report 2 transactions, from Jun 25, 2025 to Jun 24, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Kelly Michael's filings is in SAN DIEGO, CA.
Recent filings by Kelly Michael
Other insiders filing for ARS Pharmaceuticals, Inc. (SPRY)
- Casale Donn, President and CEO
- Smith Margaret Ekins, Chief Commercial Officer
- RA CAPITAL MANAGEMENT, L.P., Director
- Dadoo Rajeev, Director
- Shah Pratik, Director
- Islam Saqib, Director